Skip to Main Content

Paper Details

Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
Eur J Prev Cardiol
24
2021
Author NameAffiliation
Deepak L BhattBrigham and Women's Hospital Heart and Vascular Center and Harvard Medical School
Matthew T RoeDuke Clinical Research Institute, Duke University Medical Center
  • 1 - 2

Datasets

Release 1.2